Does a One-Site CDMO Make a Difference in Drug Development?
A one-site CDMO is where GMP, R&D and manufacturing all operate on one site, making the movement of projects streamlined.
PR
Tech Transfer in Late-Stage Oral Solid Dose Projects: Lessons Learnt and Best Practices from a CDMO Perspective
Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the drug development lifecycle. For CDMOs, it’s a moment where scientific precision meets operational discipline.
Upperton Wins at European Celebration of CDMO Excellence: Winner of Small Molecule Dosage Form Category
Upperton announces its recognition as winner of the Small Molecule Dosage Form category at the inaugural European CDMO Leadership Awards.
Upperton Expands High Precision Filling Capability at Nottingham Facility
Upperton has increased its filling capability with the installation of the Fill2Weight gravimetric powder filling machine from 3P innovation
How to Evaluate CDMO Communication Before You Commit: A Framework for Biotechs
By using our framework , sponsors can identify partners who don’t just deliver projects, but build relationships that last.
From Molecule to Market: Understanding the Roles of CROs, CMOs, and CDMOs
What exactly is the difference between a CDMO, a CRO, and a CMO? Each plays a vital role in the life sciences ecosystem.
Upperton Pharma Solutions Raises over £4,000 for Children’s Charity, Rainbows Hospice
Upperton Pharma have raised over £4,000 for Rainbows, the children’s hospice serving families in Loughborough and across the East Midlands.
Sniffing Out Solutions in the Nasal Drug Delivery Revolution
The nose to brain pathway can be leveraged to unlock new therapeutic possibilities. Learn about the opportunities of N2B delivery.
What to Expect from Upperton at CPHI Frankfurt 2025
CPHI Frankfurt is one of the most anticipated events in the pharmaceutical calendar. Upperton is proud to be exhibiting.
The New Rules of CDMO Partnerships: What Biotechs Should Be Looking for Next
Biotech companies today seek long-term development partners who can help to de-risk supply chains, accelerate time-to-market.